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effects are usually screened with rela-
tively high doses, enabling evaluation of 
cell viability, apoptosis, ROS-production, 
and other biomarkers related to cellular 
stress.[4,5]
Macrophages are among the first 
responders to foreign insults. They orches-
trate immune responses by secreting 
inflammatory cytokines, which, in turn, 
help to recruit other immune cells. More-
over, they stimulate antigen-presenting 
cells (APC) to facilitate T-cell activation 
and adaptive immunity. Macrophages are 
extremely plastic cells, able to switch their 
phenotype after certain stimuli.[6,7] After 
encountering a foreign molecular pat-
tern, macrophages produce a specific set 
of signals, thus determining the matura-
tion and polarization status of the newly 
recruited immature cells such as mono-
cytes. By modulating the expression of 
immune genes and secretion of cytokines, 
macrophages are able to adjust the micro-
environment, boosting specific immune 
responses.[8] Even though the purpose of 
macrophages as central mediators of immune system is well 
recognized and has been extensively characterized, nanoma-
terial-mediated macrophage polarization and programming is 
still largely unknown.[9]
CNM can induce inflammatory responses in vitro as well as 
in vivo.[10,11] Nevertheless, the dose and time-dependent immu-
nomodulation of CNM is still largely missing. Instead of short, 
acute-phase toxicity studies, longer exposure time points need to 
be considered in order to understand changes in the cell pheno-
types as well as the activation of adaptive immune response. This 
was demonstrated, for example, by Parise et al., who concluded 
that 48 h in vitro exposure is necessary to identify 22 sensitizers 
based on the altered gene expression levels in macrophages.[12] 
Possibly harmful nanomaterials with carefully adjusted, non-
toxic doses can also exert immunomodulatory effects, by 
increasing or decreasing the activation of the immune system.[13]
In year 2000, Mills et  al. suggested a new classification of 
macrophages, including inflammation-promoting M1-type 
and healing M2-type macrophages.[14] Since then, based on 
activated biomarkers, several studies distinguishing different 
types of macrophage populations as well as suggesting new 
populations, such as M3-type and tumor-associated mac-
rophages (TAM), have been published.[6] Widely accepted 
M1 markers include secretion and expression of TNF, IL-1β, 
Toxic effects of certain carbon nanomaterials (CNM) have been observed in 
several exposure scenarios both in vivo and in vitro. However, most of the 
data currently available has been generated in a high-dose/acute exposure 
setup, limiting the understanding of their immunomodulatory mechanisms. 
Here, macrophage-like THP-1 cells, exposed to ten different CNM for 48 h 
in low-cytotoxic concentration of 10 µg mL−1, are characterized by secretion 
of different cytokines and global transcriptional changes. Subsequently, the 
relationships between cytokine secretion and transcriptional patterns are 
modeled, highlighting specific pathways related to alternative macrophage 
activation. Finally, time- and dose-dependent activation of transcription and 
secretion of M1 marker genes IL-1β and tumor necrosis factor, and M2 marker 
genes IL-10 and CSF1 is confirmed among the three most responsive CNM, 
with concentrations of 5, 10, and 20 µg mL−1 at 24, 48, and 72 h of exposure. 
These results underline CNM effects on the formation of cell microenviron-
ment and gene expression leading to specific patterns of macrophage polari-
zation. Taken together, these findings imply that, instead of a high and toxic 
CNM dose, a sub-lethal dose in controlled exposure setup can be utilized to 
alter the cell microenvironment and program antigen presenting cells, with 
fascinating implications for novel therapeutic strategies.
1. Introduction
Several types of carbon nanomaterials (CNM) are known to 
induce inflammatory responses in vitro and in vivo.[1–3] Toxic 
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IL-6, IL-8, and IL-12.[8,15,16] M2 phenotype, on the other hand, 
is further divided into (at least) three subsets, M2a (Th2-type, 
killing), M2b (regulatory macrophages), and M2c (tissue 
remodeling, wound healing, matrix deposition). Expression or 
secretion of genes, such as TGF-β, CSF1, and DC-SIGN are 
considered M2-markers together with cytokines IL-10 and/or 
CCL18.[17,18]
Here, we first exposed PMA-differentiated THP-1 mac-
rophage-like cells to non-lethal dose of 10 µg mL−1 of ten CNM 
(Table  1). After 48 h exposure, we examined the subsets of 
induced markers linked to classically activated M1- and alterna-
tively activated M2-type macrophages.
We found distinct phenotypic markers to be regulated, sug-
gesting that macrophages are able to modulate and program 
themselves depending on the CNM exposure, as well as to 
change their signaling cascades by time. To confirm a dose and 
time related polarization effect, we further validated applicable 
M1/M2 markers by RT-qPCR and U-Plex immunoassay with 
the three most provoking CNM: graphite nanofibers (GNF), 
rigid and long multiwalled carbon nanotubes (rCNT), and short 
multiwalled carbon nanotubes (Baytubes). Based on our pre-
vious results, we focused on three low-cytotoxic CNM concen-
trations (5, 10, and 20 µg mL−1), normalized across the different 
nanomaterials based on their phenotypic effects in vitro.[19] We 
focused on three long time points (24, 48, and 72 h), to ensure 
adequate presentation of all the tested nanoparticles with the 
cells as well as to optimize the observation of macrophage 
adaptation.
2. Results and Discussion
2.1. Macrophages Respond to CNM Exposure by Secreting 
Distinct Sets of Cytokines
As previously reported, the concentration of 10 µg  mL−1 used 
in this study is suitable to investigate fine immunomodulatory 
effects of CNM, for it does not significantly impact on the cell 
viability and metabolism (Figure S3 in Scala et  al.[19]). Similar 
results on MWCNT-induced cytotoxicity have been shown also 
before, with concentrations ranging between 1 and 10 µg mL−1 
on THP-1 and BEAS-2B cells.[20]
We first focused on the possibility that CNM exposure would 
trigger patterns of cytokine secretion. For this, IL-1α, IL-1β, 
IL-4, IL-5, IL-6, IL-10, IL-17, IFNγ, and TNF were quantified in 
the cell culture supernatant after 48-h exposure.
Seven out of ten nanomaterials in the panel did not induce 
any significant cytokine secretion above the detection limits 
of the assay. Thus, we further focused on graphite nanofibers 
(GNF), rigid and long multiwalled carbon nanotubes (rCNT), 
and short multiwalled carbon nanotubes (Baytubes), which 
exerted detectable increase in cytokine secretion (Figure 1A).
Based on these results, GNF was the only material in the 
panel inducing strong secretion of acute-phase pro-inflamma-
tory tumor necrosis factor (TNF), a marker of classically acti-
vated macrophages (M1), usually induced by lipopolysaccharide 
(LPS) or pathogen stimuli. Also, the anti-inflammatory cytokine 
Interleukin 10 (IL-10) and the pro-inflammatory cytokine Inter-
leukin 1β (IL-1β) was found to be significantly secreted after GNF 
exposure, suggesting acute phase response to GNF. rCNT expo-
sure, on the other hand, did not trigger TNF secretion at 48 h 
exposure, but resulted in a sharp increase of pro-inflammatory 
cytokine IL-1β as well as anti-inflammatory cytokine IL-10. 
Absence of TNF secretion suggests, for example, inhibition 
through secretion of anti-inflammatory cytokine IL-10.[21,22] Bay-
tubes instead, caused mild secretion of IL-10, but no significant 
secretion of the M1 cytokines IL-1β or TNF.
All the remaining 7 CNM screened in this study did not 
exert any significant cytokine secretion. We could not iden-
tify an individual CNM intrinsic property that would straight-
forwardly explain cellular unresponsiveness, suggesting that 
several features, such as shape, aspect ratio, and surface area, 
affect, in combination, macrophage activation, as proposed also 
earlier.[23–25]
2.2. CNM Exposure Modulates Cytokine Transcription  
in Macrophages
In order to test the hypothesis that the induced cytokine secre-
tion would also correspond to induction of transcription, we 
further examined the cytokine changes at the transcriptional 
level (Figure  1B; Table S1, Supporting Information). We fur-
ther focused on transcriptional responses caused by rCNT, 
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Table 1. Carbon nanomaterials and their properties.
Material name Producer Acronym Type Length  
[nm]
Diameter  
[nm]
Surface  
area [m2 g−1]
Aspect ratio
Graphite nanofibers (Sigma) Sigma-Aldrich GNF Fiber 10 000 140 32 71
Multiwalled carbon nanotube (Mitsui) Mitsui & Co. rCNT Tube 13 000 50 22 260
Multiwalled carbon nanotube (Bayer) Bayer Material Science Baytubes Tube 1000 15 204 69
Carbon black (Evonik) Evonik Industries/Degussa CBL Particle 14 14 265 1
Fullerene C60 (MTR) MTR Ltd. FUL Sphere 100 100 20 1
Single-walled carbon nanotube (Sigma) Sigma-Aldrich SIG_SW Tube 50 000 1 567 45 450
Single-walled carbon nanotube (SES) SES research SES_SW Tube 1500 2 436 750
Multiwalled carbon nanotube (SES) SES research SES_MW Tube 1500 20 60 75
Multiwalled carbon nanotube (Cheaptubes) Cheaptubes Inc. CHT Tube 30 000 12 180 2600
Multiwalled carbon nanotube (Sigma) Sigma-Aldrich SIG_MW Tube 100 000 15 119 6660
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GNF, and Baytubes, since they elicited measurable, significant 
changes also in cytokine secretion.
In the rCNT-exposed macrophages, both secreted cytokines 
IL-10 and IL-1β appeared to be also upregulated at the tran-
scriptional level. TNF secretion was, in fact, strongly activated 
by GNF, but interestingly no transcriptional level activation 
was noted after 48 h exposure. As stated previously, the strong 
IL-10 secretion in case of GNF exposure might diminish the 
acute phase response by suppressing the production of TNF, 
triggering a negative feedback loop. Significant downregula-
tion of TNF was, on the other hand, appreciated after exposure 
to Baytubes. Similarly, IL-10 was secreted in response to GNF 
exposure, but downregulation was detected after 48 h at the 
transcriptional level. Reduced expression suggests weakened 
inflammation, mediated by the action of anti-inflammatory 
cytokines such as IL-10, as suggested also in other studies.[7,26,27] 
On the other hand, we found IL-1β to be significantly secreted as 
well as transcribed after 48 h exposure to GNF. This is expected, 
for IL-1β is known to be regulated through an autocrine positive 
loop.[28,29] In our experimental model, the PMA-differentiation 
might be able to trigger IL-1β secretion, but does not seem to 
affect our observations at 48 h, since in Baytubes exposure, the 
IL-1β expression was found significantly downregulated, and no 
secretion was detected even though Baytube-exposed cells were 
treated similarly with PMA before the exposures. In addition, 
Baytubes caused only mild secretion of IL-10, but no transcrip-
tional activation of the anti-inflammatory cytokine, suggesting 
mild, acute phase response with immunosuppressive effect at 
48 h. In addition, we observed transcriptional induction of IL-6 
by rCNT and GNF, but no detectable secretion (Figure 1A,B).
The differences between secretion and expression suggest 
that the changes in the microenvironment, probably rapidly 
established upon exposure as an acute response, sustain cell 
activation also after 48 h. In order to clarify the discrepancies 
in secretion and expression patterns, a detailed screening of 
time-related kinetic responses could be the focus of further 
studies. Discrepancies in secretion and expression patterns 
are also important to consider when investigating longer in 
vitro exposures. In some cases, also nanomaterial-related assay 
interference can result in inconsistent cytokine expression and 
secretion measurements. For example, cytokine adsorption to 
the CNM surface could be speculated as a reason for undetected 
IL-6, as suggested by Dilger et  al.[30] However, as described in 
Section 2.5, we noted consistent dose-dependent secretion pat-
terns of the cytokines of our interest, suggesting that this could 
be a marginal problem in our experimental setup.
Alterations between cytokine secretion and gene expression 
in the same macrophage population after exposure advocates 
the possibility that by time macrophages adapt in a specific 
microenvironment by adjusting the polarization status toward 
M1 or M2 type.
2.3. Altered Pathways Reflect Macrophage Activation 
and Suggest Macrophage Polarization
We next hypothesized that the establishment of different 
cytokine-driven microenvironments could further contribute to 
distinct expression patterns in macrophages, thus facilitating 
their polarization toward M1, M2, and mixed M1/M2 types.
Thus, the differentially expressed genes from microarray 
analysis (p-value < 0.05, |logFC|  >0.58) were characterized 
in search of over-represented biological functions (Figure  2; 
Tables S1 and S2, Supporting Information).
In order to recognize unique responses to distinct CNM, 
we compared the transcriptomic alterations caused by GNF, 
Baytubes, and rCNT against those produced by the other mate-
rials in our screening. We found 128, 74, and 215 differentially 
expressed unique genes due to GNF, Baytubes, and rCNT, 
respectively (“Exclusive genes” sheet in Table S2, Supporting 
Information). Based on the over-represented Gene Ontology 
terms, the exclusive gene sets were underlining M1/M2 status 
(Figure  2). GNF activated several pro-inflammatory and IL-1β-
related pathways (Figure  2A; “GNF exclusive pathways” sheet 
in Table S2, Supporting Information), Baytubes elicited TGF-
β2 production (Figure 2B; “Baytubes exclusive pathways” sheet 
in Table S2, Supporting Information), whereas rCNT triggered 
chemotaxis and cytokine-mediated pathways (Figure 2C; “rCNT 
exclusive pathways” sheet in Table S2, Supporting Information).
When studied at the level of activated pathways and func-
tional annotations, GNF, rCNT, and Baytubes showed inter-
esting associations to macrophage polarization (Figure  2; 
Table S2, Supporting Information). For example, pathways 
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Figure 1. Expression and secretion patterns of the ten CNM of 48-h expo-
sure: A) significant (p-value 0.05) cytokine secretion denoted with red 
color; B) significant (p-value 0.05) expression denoted with red as upregu-
lated, green as downregulated. Grey areas are indicating no significant 
changes in secretion or expression.
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related to glucocorticoid response were found to be associated 
only to rCNT exposure (Table S2, Supporting Information). 
Glucocorticoids are included in the M2-macrophage category, 
having anti-inflammatory and immunosuppressive effects.[31]
GNF-enriched pathways contained numerous cholesterol-
related pathways (“GNF enrichments” sheet in Table S1, Sup-
porting Information). Macrophages promote atherosclerosis 
and plaque formation by maintaining pro-inflammatory micro-
environment.[17] Imbalance in cholesterol homeostasis increases 
the risk of atherosclerosis.[32] Interestingly, the cholesterol 
transporter genes ABCA1 and ABCG1 (Table  2), both associ-
ated to atherosclerosis,[32] were found significantly upregulated 
after GNF exposure and are also found to be activated in iron-
related macrophage polarization, namely hemoglobin-associ-
ated macrophage (M(Hb)).[17,33–35] Furthermore, the expression 
of CCL5, secreted by M1-macrophages, was induced exclusively 
after GNF exposure (Table 2). CCL5 is an expressed feature of 
inflammatory disorders such as atherosclerosis.[36,37] Unique, 
differentially expressed genes (DEGs) associated solely to GNF 
further supported the outcome, by activating pathways related 
Small 2020, 1907609
Figure 2. Biological Process Gene Ontologies enriched by exclusive genes relative to a) GNF, b) Baytubes, and c) rCNT exposures. Bars are sorted by 
log of the p-value from the Fisher’s exact test multiplied by the z-score of the deviation from the expected rank. Statistics and lists of all exclusive genes 
and gene ontologies are reported in Table S2, Supporting Information.
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to IL-1β production and secretion (Figure  2; Table S2, Sup-
porting Information).
Baytubes-associated top-ranked, enriched pathways instead 
included immunity and virus-related pathways such as 
response and defense response to viruses, including influ-
enza A, hepatitis C, herpes simplex infection, and measles, 
thus suggesting possible sensing mechanisms against viruses 
(“Baytubes enrichments”-sheet in Table S1, Supporting Informa-
tion). It could be speculated that the size of Baytubes is reflecting 
certain size components of some viruses. This is also supported 
by the enriched oligoadenylate synthetase pathway. Oligoad-
enylate synthetases are antiviral enzymes that degrade viral and 
host RNA.[38] It has been shown that viruses can trigger M2-type 
activation and IL-10 expression, for example, in case of swine 
fever virus, hepatitis C, herpesviruses, and measles virus.[39–43]
2.4. Transcriptional Alterations Suggest Macrophage 
Polarization
In order to understand the specific alterations in macrophage 
activation status, genes known to be associated to M1 and M2 
type macrophages were more closely examined (Table 2).
Classically activated M1-type macrophages secrete a set of 
pro-inflammatory cytokines such as TNF, CXCL8, IL-1β, IL-6, 
IL-12, and IL-23.[8] Based on the transcriptional alterations, GNF 
induced pro-inflammatory, M1-type of macrophage polarization 
by inducing secretion of TNF and IL-1β as well as the expres-
sion of CXCL8, IL-6, and Il-1β. Furthermore, CCL5, secreted in 
high concentrations by M1 macrophages,[37] was differentially 
expressed only after GNF exposures.
rCNT triggered altogether the strongest response by acti-
vating several inflammatory genes such as IL-1β, TRAF1, 
SOCS3, IL-24, and CXCL8 as well as stimulated the secretion of 
IL-1β and IL-10. Furthermore, the following M2-marker genes 
were found to be differentially expressed: IL-4I1, IL-10, CCL18, 
IL-1RN, CSF1 (M-CSF), ARG2, VEGFA, MMP9, CXCL2. The 
patterns of transcriptional regulation observed after rCNT expo-
sure are compatible with both M1 and M2 types of activation, 
M2-type being more pronounced (Table  2). rCNT induced the 
expression of cytokine IL-6, which is active in classically acti-
vated (M1) and alternatively activated (M2) macrophages.[17] 
Also, IL-10 and CCL18, known to be active in M2-macrophages, 
were overexpressed after rCNT exposure. Moreover, IL-4I1 
gene, a novel regulator of M2 polarization, was found to be sig-
nificantly induced by rCNT.[44] Il-1RN, an M2-cytokine that com-
petes for the same receptors with IL-1β, was similarly highly 
expressed after rCNT exposure, suggesting yet another mech-
anism of inhibiting the pro-inflammatory responses. In addi-
tion, NF-κB inhibitor (NFKBIA), an inflammation regulator 
was significantly upregulated at 48 h rCNT exposure. NFKBIA 
activation suggests inhibition of transcription factor NF-κB, a 
key regulator in infection-related immune responses at the 48 h 
exposure. Instead, IFNγ-activated adhesion molecule (ICAM1), 
considered as M1-type marker,[31] was strongly induced by rCNT 
exposure. We have previously shown that rCNT activates Th2-
type of response in mouse lung by promoting secretion of Th2 
cytokines IL-4, IL-5, and IL-13.[45,46] M2a-type macrophages 
stimulated by the aforementioned cytokines, are further able 
to express, for instance, IL-1RN (Anakinra), IL-10, TGF-β, and 
CSF1.[8] We found the same molecules induced after 48 h expo-
sure to rCNT in vitro. The CSF1 gene, which leads to homeo-
static or anti-inflammatory M2-like phenotype,[31,47] was highly 
expressed in rCNT-exposed macrophages. Regulatory (M2b) 
macrophages, have unbalanced levels of IL-10 and IL-12, down-
regulating IL-12 and producing IL-10 at the same time.[16,17] 
This was evident also in our experiments, as rCNT induced 
IL-10 but downregulated IL-12A. Regulatory M2-type macro-
phages are potent inhibitors of inflammation, even though 
they might retain the ability to produce also pro-inflammatory 
cytokines.[16] Along the same lines, also our results suggest that 
rCNT might cause mixed and unbalanced macrophage pheno-
types triggering M2 activation as well as classically activated 
M1 macrophages. This was also concluded by Meng et al. with 
mouse macrophage cell line RAW264.7 exposed to MWCNT 
for 24 h, revealing M1/M2 mixed status.[48] By following our 
previous finding that rCNT can cause unconventional Th-2 
type of allergic response in vivo,[46] it can be hypothesized that 
in complex tissues, with multiple cell types sharing the same 
microenvironment, a clearer M2-type response can be achieved, 
where Th2-type signaling molecules are more prominently 
induced.
Exposure to Baytubes triggered secretion of IL-10 but 
resulted in significant downregulation of pro-inflammatory 
cytokines TNF and IL-1β. Instead, upregulation of M2-cytokines 
Small 2020, 1907609
Table 2. Genes related to phenotypic markers of macrophages. Genes 
with Log2 fold change (red upregulated, green downregulated) and their 
corresponding p-values are presented.
Genes
logFC p.value logFC p.value logFC p.value
ABCA1 0,009 <0,001 0,890
ABCG1 0,005 <0,001 0,005
ARG2 0,004 0,051 0,011
CCL18 0,006 0,222 0,210
CCL5 0,262 0,005 0,001
CLEC12b 0,002 0,008 0,192
CXCL2 0,054 0,314 0,658
CXCL3 <0,001 0,167 0,462
CXCL8 (IL-8) 0,000 0,060 0,244
DC-SIGN 0,976 0,480 0,208
ICAM1 <0,001 0,040 0,032
IFNy 0,525 0,331 0,516
IL-10 <0,001 0,023 0,075
IL-12 (A) 0,058 0,568 0,019
IL-1a 0,001 0,005 0,019
IL-1b <0,001 <0,001 <0,001
IL-1RN <0,001 0,177 0,061
IL-20 0,048 0,768 0,825
IL-23 0,173 0,553 0,457
IL-24 <0,001 0,225 0,640
IL-4 0,469 0,489 0,952
IL-5 0,090 0,038 0,712
IL-6 0,022 0,027 0,181
IL4I1 <0,001 0,267 0,001
M-CSF 0,001 0,049 0,067
MMP9 0,001 0,050 0,702
NFKB1 0,002 0,295 0,116
NFKB2 0,008 0,165 0,010
NFKBIA <0,001 0,126 0,038
SOCS3 <0,001 0,103 0,127
TGFB1 0,864 0,521 0,747
TGFB2 0,005 0,042 0,001
TLR8 0,044 0,027 0,097
TNF 0,047 0,151 <0,001
TNFAIP3 <0,001 <0,001 0,002
TNFAIP6 <0,001 0,203 0,236
TNFAIP8 0,002 0,002 0,003
TRAF1 0,022 0,928 0,014
VEGFA <0,001 0,006 0,067
rCNT GNF Bay
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TGF-β2 and IL-4l1 was observed. TGF-β is known to activate 
M2a and M2c-types of macrophages,[17,49] whereas IL-4I1 is a 
novel regulator of M2 polarization.[44] Expression of IL-4l1 and 
strong downregulation of pro-inflammatory cytokines IL-1β and 
TNF suggest M2 polarization after Baytubes exposure. On the 
other hand, IL-10 expression was not detected despite its mild 
secretion was noted. Secretion of IL-10 suggests wound healing 
or regulatory M2 type of activation. According to Italiani and 
Boraschi, M2 macrophages in vitro can be characterized by high 
levels of IL-10 and TGF-β, and low levels of IL-12 and IL-23.[47] 
TGF-β is believed to play a role in alternative macrophage acti-
vation.[49] While we could observe IL-10 secretion, upregula-
tion of TGF-β2 expression, and down regulation of IL-12A after 
Baytubes exposure, no significant regulation of IL-23 expres-
sion was observed.
We compared our findings on the selected M1/M2 genes 
reported in Table 2 with the results from previous studies car-
ried out on murine and human primary monocyte derived 
macrophages, treated either with LPS (M1 activation) or with 
IL-4 (M2 activation).[50–53] The vast majority (31/39) of the genes 
reported in our panel (Table 2) have a consistent expression pat-
tern and are identified as M1 or M2 markers also in the com-
plementing studies. For example, CCL5, reported to be strongly 
activated by LPS, indeed is activated by GNF but not the other 
CNMs in our screening. Likewise, IL-1b was induced by LPS 
treatment, similarly to the GNF and rCNT exposures. Overall, 
more commonalities in gene expression patterns were not sur-
prisingly noted between LPS-treated human monocyte derived 
macrophages, GNF- and rCNT-exposed macrophage-like THP-1 
cells (Table S3 and Figures S1 and S2, Supporting Information).
Taken together, our observations on the secretion patterns 
of cytokines and transcriptional alterations suggest that GNF 
might induce macrophage M1 type activation, Baytubes may 
promote M2 type of activation, while rCNT might exert a hybrid 
M1/M2 macrophage phenotype.
2.5. CNM Exert Macrophage Polarization  
in a Dose- and Time-Dependent Manner
Our observations with 48-h exposure suggest that macrophages 
stimulated with GNF, rCNT, or Baytubes develop distinct 
microenvironments, which are able to further induce macro-
phage polarization.
To confirm time- and dose-related effect on the possible 
polarization, we chose IL-1β and TNF genes to illustrate 
M1-type activation and IL-10 and CSF1 to signify M2-type of 
macrophage polarization. We measured the changes in secre-
tion and expression of the four marker genes with three dif-
ferent doses of 5, 10, and 20 µg mL−1 at three different exposure 
time points of 24, 48, and 72 h.
GNF-exposed cells secreted and expressed IL-1β and TNF 
especially after 24- and 72-h exposures, whereas M2 markers 
(IL-10 and CSF1) were diminished in a time-dependent manner 
(Figure 3). Moreover, no IL-10 expression was observed at any of 
the measured time points, whereas secretion was progressively 
decreasing in time. This suggests that IL-10 might be an ear-
lier, acute response before the first measured 24-h time point, 
and thus shows degradative pattern instead of active secretion. 
rCNT instead showed clear time- and partly dose-dependent 
accumulation of all four markers (Figure 4).
Interestingly, Baytubes activated expression and secretion of 
M2-related IL-10 after 72 h. CSF1 expression was also activated 
after 72 h with 10 and 20 µg mL−1, but no significant secretion 
was detected with any timepoint or concentration (Figure  5). 
Secretion of IL-1β was observed at all concentrations and time-
points, but no expression was detected, suggesting again ear-
lier, acute response diminishing the expression before the first 
measured time point of 24 h.
Since in our experimental setup new monocytes are not 
introduced to the culture and the initial state is the same, 
these results suggest that macrophages are able to program 
and polarize themselves, depending on the exposure and 
the cytokines present in their local environment. This agrees 
with the study by Tarique et  al. where the ability of human 
macrophages to reprogram or depolarize after alternative 
stimuli was tested.[18] Also, Lugo-Villarino et  al. and Huang 
et  al. suggested similar changes in macrophage polarization 
due to Mycobacterium tuberculosis or HIV infection.[54,55]
These results suggest that, after nanoparticle contact, 
macrophages secrete certain sets of cytokines as an acute 
response which, together with signals coming from stressed 
or apoptotic cells as well as the nanoparticles themselves, 
trigger the macrophages to redesign themselves in time. None-
theless, it should be considered that M1/M2 classification is 
oversimplified and signatures from different macrophage 
populations do not exclude each other, but often co-exist 
resulting in mixed phenotypes that further depend on the 
microenvironment.[31]
2.6. Discussion
Here we report the ability of three different CNM to induce phe-
notypic changes in a cell culture model of human macrophages.
Macrophage polarization is a dynamic process that remains 
incompletely understood.[56] Environmental factors are able to 
initiate phenotypic changes in macrophages. These include 
distinct signals from microbial products, damaged cells, gluco-
corticoid hormones, apoptotic bodies, and immune complexes. 
Additionally, polarization can be adjusted by local micro-
environmental conditions. A number of receptor-directed 
signaling pathways involving the modulation of distinct tran-
scriptional regulatory machineries are known to be involved 
in macrophage polarization.[56–58] Although our observations 
are not granular enough to resolve the whole chain of mole-
cular alterations involved in CNM polarization, we do observe 
suggestive molecular alterations. In particular, the transcrip-
tional regulatory mechanisms mediated by NF-κB, STAT3 
and HIF1/2 seem to be altered in our exposure setups. For 
example, we observed significant SOCS3, HIF-2a, and IL-10 
expression after 48 h rCNT exposure. Additionally, NF-κB acti-
vation can be detected from the 48 h exposures to rCNT and 
Baytubes. GNF activated TLR8, which is upstream to MyD88 
and NF-κB activation.[59] However, the activation of different 
pathways should be studied through receptor activation after a 
relatively short period of time, which is out of the scope of the 
current study.
Small 2020, 1907609
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Dosimetric considerations are important when com-
paring the effects of ENM in vitro. We based the selection 
of the doses used in this study on their biological effects. We 
have previously characterized the cytotoxic potential of the 
same 10 CNM (Figure S3 in Scala et  al.[19]) on THP-1 cells 
and concluded that a nominal dose of 10 µg mL−1 exerts no 
Small 2020, 1907609
Figure 3. Secretion (pg mL−1) and expression (relative quantity, RQ) levels of IL-1β, TNF, Il-10, and CSF1 with GNF concentrations of 5, 10, and 20 µg mL−1 
at 24, 48 and 72 h post-exposure compared to untreated control.
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significant cell death after 48 h exposure. For the subsequent 
experiments, we started from this observation and extended 
the range of the tested doses by halving and doubling the 
phenotypically characterized nominal dose of 10 µg mL−1. All 
the experiments reported in this study were conducted by 
plating the same number of cells (1  000  000 cells per well) 
Small 2020, 1907609
Figure 4. Secretion (pg mL−1) and expression (relative quantity, RQ) levels of IL-1β, TNF, Il-10, and CSF1 with rCNT concentrations of 5, 10, and 20 µg mL−1 
at 24, 48, and 72 h post-exposure compared to untreated control.
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at ≈85% confluency. Based on the current literature about 
nanomaterial concentration selection, in vitro studies uti-
lize higher concentrations typically ranging between 30 and 
400 µg  mL−1, usually for exposure times ranging between 
a few to 24 h maximum.[4,60,61] Our scope here was to test 
significantly lower doses at longer time points to induce 
Figure 5. Secretion (pg  mL−1) and expression (relative quantity, RQ) levels of IL-1β, TNF, Il-10, and CSF1 with Baytube concentrations of 5, 10, 
and 20 µg mL−1 at 24, 48, and 72 h post-exposure compared to untreated control.
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phenotypic changes in macrophages without exerting toxic 
effects. When working with in vitro cell culture systems, it is 
also important to control the exposure conditions to ensure 
maximal presentation of nanoparticles with adherent cells. 
Although significant efforts have been made to develop 
methods to quantify CNM deposition in cell cultures,[62–65] 
it is currently still laborious to precisely measure the exact 
CNM deposited dose.[66] Indeed, differently sized materials 
may sediment with varying speed in cell culture, as shown 
for example by Mendes et  al. in 2017. They concluded that 
larger graphite nanoflakes were more easily uptaken by the 
cells. Nonetheless, they also pointed out that endocytosis can 
be reliably detected only shortly after the exposure (within 
2–30 min) but not after longer incubation periods (>90 min). 
Our experimental procedure, based on longer time points, 
is supported by evidence recently reported by Septiadi et al., 
who clarified that the deposition of different materials is 
incremental during the first 24 h of liquid exposure in vitro, 
but it is maintained constantly in the subsequent hours/
days.[67] Furthermore, the consistency of our observations 
concerning the molecular effects in dose-dependent and 
time-dependent manner suggest that the three materials 
assayed in this study have a stable behavior across the whole 
span of our experimental setup. Moreover, we have applied 
here very robust dispersion protocols that have been largely 
used in multiple studies both in vitro and in vivo.[45,68,69]
Our experiments highlight an interesting effect of rCNT, 
which seem to exert a mixed M1/M2 phenotype on the 
THP-1 cell cultures. Our results are in line with previous 
reports limited at 24 h exposure with the same material.[48] 
However, as both this and the previous studies are con-
ducted on bulk cell populations, we are currently unable to 
clarify whether this reflects heterogeneity at the population 
or, conversely, individual cell level. Moreover, although our 
results elucidate important steps needed to exert macro-
phage polarization by CNM exposure, a number of ques-
tions remain open concerning the exact sequence of early 
molecular events taking place in this process. Some of the 
discrepancies observed between induction of expression and 
secretion of cytokines might also be due to more complex 
patterns of regulation.[70] All these aspects can be addressed 
by future studies focusing on more granular observations 
of the kinetic molecular alterations by CNM toward macro-
phage polarization.
3. Conclusions
Taken together, our results suggest that complex regulatory 
events, resulting from both ENM exposure and secondary 
microenvironment changes, trigger macrophages to move 
toward M1 and M2 activation. Possible future implications of 
our results may include the notion that also “toxic exposures” 
might be utilized in a beneficial way by lowering the tradi-
tional doses used in toxicology testing to a non-lethal level. 
Thus, our findings emphasize the importance of relentlessly 
evolving microenvironment in response to prolonged exposure 
scenarios.
4. Experimental Section
Nanomaterials: All the nanomaterials used in the study have been 
previously characterized and reported in NANOATLAS by Vippola et al. 
and in our previous publications.[45,46,68,71,72] Suppliers and material 
characteristics are described in Table 1.
In Vitro Cultures: THP-1 cells (ATCC TIB-202) were grown in complete 
RPMI media, supplemented with 10% FBS and 1% Ultraglutamine. 
Cells were grown in culturing flasks (75 cm2) at 37 °C in a humidified 
atmosphere of 5% CO2. THP-1 cells were differentiated with 50 nm 
PMA (phorbol-12-myristate-13-acetate) for 48 h before nanomaterial 
exposures.
CNM Suspensions: Stock suspensions containing 1 mg  mL−1 of 
nanomaterial were prepared by weighing the materials into glass tubes 
and diluting them with 1% FBS-PBS. The suspensions were sonicated 
2 × 15 min in bath sonicator (Elmasonic, USA) at room temperature. 
Dilutions were prepared to complete RPMI media supplemented with 
1% FCS. Dilutions were sonicated for 15 min and vortexed before the 
exposures. Exposures were performed in 6-well plates with 1  000  000 
cells per well in 2.0 mL of RPMI media supplemented with 10% FBS. 
Exposures were conducted as triplicates with final concentrations of 5, 
10, and 20 µg of ENM per mL. Cell viability and the preliminary results 
after 48 h exposures are reported in Scala et al.[19 After 24-, 48-, and 72-h 
incubation, the supernatant was collected and frozen in −80 °C. The cells 
were lysed on wells with lysing buffer and RNA was extracted according 
to Qiagen RNEasy mini kit protocol (Qiagen, GmbH, Hilden, Germany).
Cytokine Secretion: Supernatants from the cell exposures were used 
to study the secretion of cytokines after 48-h exposure. Q-plex Human 
Cytokine High Sensitivity (9-Plex) (Quansys Biosciences, Utah, USA) 
assay was performed according to the instructions provided by the 
vendor. The following cytokine concentrations were measured: IL-1α, 
IL-1β, IL-4, IL-5, IL-6, IL-10, IL-17, IFNγ, and TNF.
Microarray Data: mRNA transcriptome data (Agilent SurePrint 
G3Human DNA microarrays) by Scala et al.[19] was used in the study and 
are accessible free of charge through ArrayExpress accession number: 
E-MTAB-6396.
Transcriptomics Analyses: Transcriptomics data analysis was performed 
as previously described.[19] Briefly, after quality check, data was normalized 
with the quantile method and unreliable probes were discarded. The 
effect of technical batches was corrected by using Combat method and 
probes mapping to the same REFSEQ ID were summarized by their 
median value.[73] Linear models, followed by eBayes pairwise comparison, 
were applied in order to find differentially expressed genes.[74]
Lists of differentially expressed genes (p-value < 0.05, |logFC|>0.58) 
were further analyzed with DAVID Functional Annotations analyses 
(Table S1, Supporting Information),[75] in search of significantly 
overrepresented biological themes. Exclusive DEGs to GNF, Baytubes 
and rCNT were imported to EnrichR tool.[76] Complete list of pathways 
and their statistics can be found from Table S2, Supporting Information.
RT-qPCR Validation: Complementary DNA (cDNA) was synthesized 
from 500 ng of total RNA in a 25 µL reaction, utilizing MultiScribe 
Reverse Transcriptase and random primers (The High Capacity cDNA 
Archive Kit, Applied Biosystems) according to the manufacturer’s 
protocol. The synthesis was performed in a 2720 Thermal Cycler (Applied 
Biosystems, Carlsbad, CA, USA) with thermal cycles of 25 °C for 10 min 
and 37 °C for 120 min (Thermal Cycler, Applied Biosystems). Primers 
and probes (18S rRNA, IL-10, TNF, IL-1β, CSF1) for PCR analysis were 
purchased as predeveloped assay reagents from Applied Biosystems. 
The PCR assays were performed with a Relative Quantification 7500 Fast 
System (7500 Fast Real-Time PCR system, Applied Biosystems, Foster 
City, CA, USA). Amplifications were done in 11 µL reaction volume 
containing TaqMan universal PCR master mix and primers by Applied 
Biosystems and 1 µL of cDNA sample. Ribosomal 18S was utilized as 
a housekeeping gene. The expression of sample mRNA were analyzed 
using the comparative CT (2−(ddCt)) method,[77] and normalized to 
the reference gene 18S to obtain the relative quantity (RQ). Relative 
expression levels were calculated between treated and control groups.
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Immunoassay Validation: Supernatants from the cell exposures 
were used to confirm the secretion of cytokines IL-1β, TNF, IL-10, and 
CSF1 after 24-, 48-, and 72-h exposure. U-PLEX immunoassay platform 
(MesoScale Diagnostics, LLC. Maryland, USA) was performed according 
to the instructions provided by the vendor. Measurements below the 
detection range were filtered out. Moreover, values above or below 
the fit curve range and Calc.Conc. CV values > 30 were removed from 
the analysis. Analysis of variance (ANOVA), followed by a Fisher Least 
Significant Different (FisherLSD) post hoc test was measured for each 
cytokine. The ANOVA was performed through the aov-R function using 
the stats package, while the FisherLSD test was performed by the Fisher 
PostHocTest function of the R/CRAN package DescTools.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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